NCT06297616

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 128 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	LY3841136	Administered SC
DRUG	LY3841136-Placebo	Administered SC
DRUG	Tirzepatide	Administered SC
DRUG	Tirzepatide-Placebo	Administered SC

Timeline

• Start date: 2024-04-15
• Primary completion: 2025-11-21
• Completion: 2025-11-21
• First posted: 2024-03-07
• Last updated: 2026-01-16

Locations

3 sites across 1 country: Japan